Ultra-large Library Docking for Discovering New Chemotypes

Overview

Journal Nature

Specialty Science

Date 2019 Feb 8

PMID 30728502

Citations 315

Authors

Jiankun Lyu

Sheng Wang

Trent E Balius

Isha Singh

Anat Levit

Yurii S Moroz

Matthew J OMeara

Tao Che

Enkhjargal Algaa

Kateryna Tolmachova

Andrey A Tolmachev

Brian K Shoichet

Bryan L Roth

John J Irwin

Affiliations

Soon will be listed here.

Abstract

Despite intense interest in expanding chemical space, libraries containing hundreds-of-millions to billions of diverse molecules have remained inaccessible. Here we investigate structure-based docking of 170 million make-on-demand compounds from 130 well-characterized reactions. The resulting library is diverse, representing over 10.7 million scaffolds that are otherwise unavailable. For each compound in the library, docking against AmpC β-lactamase (AmpC) and the D dopamine receptor were simulated. From the top-ranking molecules, 44 and 549 compounds were synthesized and tested for interactions with AmpC and the D dopamine receptor, respectively. We found a phenolate inhibitor of AmpC, which revealed a group of inhibitors without known precedent. This molecule was optimized to 77 nM, which places it among the most potent non-covalent AmpC inhibitors known. Crystal structures of this and other AmpC inhibitors confirmed the docking predictions. Against the D dopamine receptor, hit rates fell almost monotonically with docking score, and a hit-rate versus score curve predicted that the library contained 453,000 ligands for the D dopamine receptor. Of 81 new chemotypes discovered, 30 showed submicromolar activity, including a 180-pM subtype-selective agonist of the D dopamine receptor.

Citing Articles

Innovative perspectives on the discovery of small molecule antibiotics.

Cardona S, Rahman A, Novomisky Nechcoff J NPJ Antimicrob Resist. 2025; 3(1):19.

PMID: 40082593 PMC: 11906701. DOI: 10.1038/s44259-025-00089-0.

Ligand-Induced Biased Activation of GPCRs: Recent Advances and New Directions from In Silico Approaches.

Hashem S, Dougha A, Tuffery P Molecules. 2025; 30(5).

PMID: 40076272 PMC: 11901715. DOI: 10.3390/molecules30051047.

A database for large-scale docking and experimental results.

Hall B, Tummino T, Tang K, Irwin J, Shoichet B bioRxiv. 2025; .

PMID: 40060496 PMC: 11888352. DOI: 10.1101/2025.02.25.639879.

Virtual library docking for cannabinoid-1 receptor agonists with reduced side effects.

Tummino T, Iliopoulos-Tsoutsouvas C, Braz J, OBrien E, Stein R, Craik V Nat Commun. 2025; 16(1):2237.

PMID: 40044644 PMC: 11882969. DOI: 10.1038/s41467-025-57136-7.

Structural bioinformatics for rational drug design.

Mozaffari S, Moen A, Ng C, Nicolaes G, Wichapong K Res Pract Thromb Haemost. 2025; 9(1):102691.

PMID: 40027444 PMC: 11869865. DOI: 10.1016/j.rpth.2025.102691.

References

de Graaf C, Kooistra A, Vischer H, Katritch V, Kuijer M, Shiroishi M . Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. J Med Chem. 2011; 54(23):8195-206. PMC: 3228891. DOI: 10.1021/jm2011589. View

Becker O, Marantz Y, Shacham S, Inbal B, Heifetz A, Kalid O . G protein-coupled receptors: in silico drug discovery in 3D. Proc Natl Acad Sci U S A. 2004; 101(31):11304-9. PMC: 509175. DOI: 10.1073/pnas.0401862101. View

Eidam O, Romagnoli C, Caselli E, Babaoglu K, Teotico Pohlhaus D, Karpiak J . Design, synthesis, crystal structures, and antimicrobial activity of sulfonamide boronic acids as β-lactamase inhibitors. J Med Chem. 2010; 53(21):7852-63. PMC: 3166525. DOI: 10.1021/jm101015z. View

Lober S, Hubner H, Gmeiner P . Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006; 16(11):2955-9. DOI: 10.1016/j.bmcl.2006.02.075. View

Kabsch W . XDS. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 2):125-32. PMC: 2815665. DOI: 10.1107/S0907444909047337. View

Ahn S, Kahsai A, Pani B, Wang Q, Zhao S, Wall A . Allosteric "beta-blocker" isolated from a DNA-encoded small molecule library. Proc Natl Acad Sci U S A. 2017; 114(7):1708-1713. PMC: 5321036. DOI: 10.1073/pnas.1620645114. View

Katz B, Elrod K, Luong C, Rice M, Mackman R, Sprengeler P . A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site. J Mol Biol. 2001; 307(5):1451-86. DOI: 10.1006/jmbi.2001.4516. View

Keseru G, Makara G . The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov. 2009; 8(3):203-12. DOI: 10.1038/nrd2796. View

Tirado-Rives J, Jorgensen W . Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. J Med Chem. 2006; 49(20):5880-4. DOI: 10.1021/jm060763i. View

10.

Congreve M, Andrews S, Dore A, Hollenstein K, Hurrell E, Langmead C . Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. J Med Chem. 2012; 55(5):1898-903. PMC: 3308197. DOI: 10.1021/jm201376w. View

11.

Tolmachev A, Bogolubsky A, Pipko S, Grishchenko A, Ushakov D, Zhemera A . Expanding Synthesizable Space of Disubstituted 1,2,4-Oxadiazoles. ACS Comb Sci. 2016; 18(10):616-624. DOI: 10.1021/acscombsci.6b00103. View

12.

Bohacek R, McMARTIN C, Guida W . The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev. 1996; 16(1):3-50. DOI: 10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.0.CO;2-6. View

13.

Carlsson J, Coleman R, Setola V, Irwin J, Fan H, Schlessinger A . Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol. 2011; 7(11):769-78. PMC: 3197762. DOI: 10.1038/nchembio.662. View

14.

Negri A, Rives M, Caspers M, Prisinzano T, Javitch J, Filizola M . Discovery of a novel selective kappa-opioid receptor agonist using crystal structure-based virtual screening. J Chem Inf Model. 2013; 53(3):521-6. PMC: 3702663. DOI: 10.1021/ci400019t. View

15.

Barelier S, Eidam O, Fish I, Hollander J, Figaroa F, Nachane R . Increasing chemical space coverage by combining empirical and computational fragment screens. ACS Chem Biol. 2014; 9(7):1528-35. PMC: 4215856. DOI: 10.1021/cb5001636. View

16.

Allen J, Yost J, Setola V, Chen X, Sassano M, Chen M . Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 2011; 108(45):18488-93. PMC: 3215024. DOI: 10.1073/pnas.1104807108. View

17.

Jones G, Willett P, Glen R, Leach A, Taylor R . Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997; 267(3):727-48. DOI: 10.1006/jmbi.1996.0897. View

18.

Powers R, Morandi F, Shoichet B . Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase. Structure. 2002; 10(7):1013-23. DOI: 10.1016/s0969-2126(02)00799-2. View

19.

Murshudov G, Vagin A, Dodson E . Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997; 53(Pt 3):240-55. DOI: 10.1107/S0907444996012255. View

20.

Enguehard-Gueiffier C, Hubner H, El Hakmaoui A, Allouchi H, Gmeiner P, Argiolas A . 2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist. J Med Chem. 2006; 49(13):3938-47. DOI: 10.1021/jm060166w. View